JP2025503641A5 - - Google Patents
Info
- Publication number
- JP2025503641A5 JP2025503641A5 JP2024541159A JP2024541159A JP2025503641A5 JP 2025503641 A5 JP2025503641 A5 JP 2025503641A5 JP 2024541159 A JP2024541159 A JP 2024541159A JP 2024541159 A JP2024541159 A JP 2024541159A JP 2025503641 A5 JP2025503641 A5 JP 2025503641A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298098P | 2022-01-10 | 2022-01-10 | |
| US63/298,098 | 2022-01-10 | ||
| PCT/US2023/060288 WO2023133543A1 (en) | 2022-01-10 | 2023-01-09 | Ras inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503641A JP2025503641A (ja) | 2025-02-04 |
| JP2025503641A5 true JP2025503641A5 (https=) | 2026-01-19 |
Family
ID=85199574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541159A Pending JP2025503641A (ja) | 2022-01-10 | 2023-01-09 | Ｒａｓ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250197423A1 (https=) |
| EP (1) | EP4463231A1 (https=) |
| JP (1) | JP2025503641A (https=) |
| KR (1) | KR20240132492A (https=) |
| CN (2) | CN118922423A (https=) |
| AR (1) | AR128234A1 (https=) |
| AU (1) | AU2023204824A1 (https=) |
| CA (1) | CA3246887A1 (https=) |
| CL (2) | CL2024002041A1 (https=) |
| CO (1) | CO2024010814A2 (https=) |
| CR (1) | CR20240276A (https=) |
| IL (1) | IL314033A (https=) |
| MX (1) | MX2024008561A (https=) |
| PE (1) | PE20241892A1 (https=) |
| TW (1) | TW202330553A (https=) |
| WO (1) | WO2023133543A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| JP2025525315A (ja) * | 2022-07-08 | 2025-08-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｋｒａｓ阻害剤として有用な大員環化合物 |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN118047797A (zh) * | 2022-11-16 | 2024-05-17 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AR134354A1 (es) * | 2023-11-16 | 2026-01-07 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento del cáncer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025213065A1 (en) * | 2024-04-05 | 2025-10-09 | Revolution Medicines, Inc. | Peptide conjugates |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL322454A (en) * | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| AU2020377925A1 (en) * | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022217053A1 (en) * | 2021-04-09 | 2022-10-13 | Revolution Medicines, Inc. | Use of sos1 inhibitors with ras inhibitors to treat cancers |
| TW202309052A (zh) * | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| AU2022281343A1 (en) * | 2021-05-25 | 2023-11-30 | Revolution Medicines, Inc. | Methods for inhibiting ras |
-
2023
- 2023-01-09 CN CN202380026429.5A patent/CN118922423A/zh active Pending
- 2023-01-09 WO PCT/US2023/060288 patent/WO2023133543A1/en not_active Ceased
- 2023-01-09 TW TW112100804A patent/TW202330553A/zh unknown
- 2023-01-09 EP EP23704026.6A patent/EP4463231A1/en active Pending
- 2023-01-09 MX MX2024008561A patent/MX2024008561A/es unknown
- 2023-01-09 AR ARP230100052A patent/AR128234A1/es unknown
- 2023-01-09 CA CA3246887A patent/CA3246887A1/en active Pending
- 2023-01-09 IL IL314033A patent/IL314033A/en unknown
- 2023-01-09 PE PE2024001555A patent/PE20241892A1/es unknown
- 2023-01-09 KR KR1020247026507A patent/KR20240132492A/ko active Pending
- 2023-01-09 AU AU2023204824A patent/AU2023204824A1/en active Pending
- 2023-01-09 JP JP2024541159A patent/JP2025503641A/ja active Pending
- 2023-01-09 CN CN202411889987.7A patent/CN119798279A/zh active Pending
- 2023-01-09 CR CR20240276A patent/CR20240276A/es unknown
-
2024
- 2024-07-04 CL CL2024002041A patent/CL2024002041A1/es unknown
- 2024-07-10 US US18/769,009 patent/US20250197423A1/en active Pending
- 2024-08-08 CO CONC2024/0010814A patent/CO2024010814A2/es unknown
-
2025
- 2025-03-28 CL CL2025000954A patent/CL2025000954A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503641A5 (https=) | ||
| AU2016270907B2 (en) | Inhibitors of Bruton's tyrosine kinase | |
| ES2376424T3 (es) | Inhibidores de tirosina cinasa de bruton. | |
| JP2024517847A5 (https=) | ||
| JP2025528836A (ja) | ピリドピリミジンＫＲａｓ阻害剤 | |
| JP2023052201A5 (https=) | ||
| ES2426599T3 (es) | Formulación oral anticáncer | |
| CN109310686A (zh) | 可溶性C5aR拮抗剂 | |
| HK1249510A1 (en) | Substituted amino triazoles useful as human chitinase inhibitors | |
| JP6793859B2 (ja) | 同位体濃縮３−アミノ−１−プロパンスルホン酸誘導体及びその使用 | |
| NZ732538A (en) | Macrocyclic compounds as irak1/4 inhibitors and uses thereof | |
| BR112021001618A2 (pt) | antagonistas tlr7/8 e usos dos mesmos | |
| JP2025525281A (ja) | 五員縮合六員化合物、製造方法、医薬組成物及び応用 | |
| RU2005134006A (ru) | Производные 4-(4-{гетероциклилалкокси}фенил0-1-(гетероциклилкарбонил)пиперидина и родственные соединения как антагонисты гистамина н3 для лечения неврологических заболеваний, таких как болезнь альцгеймера | |
| KR20040029057A (ko) | Ｃｃｒ5 길항제로서 유용한 피페리딘 유도체 | |
| JP2025509286A5 (https=) | ||
| JP2020511450A5 (https=) | ||
| EP4519259A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| CA3256666A1 (en) | HETEROBORCTIONAL TETRAHYDROISOQUINOLINE BCL-X DEGRADING AGENTS | |
| TWI839374B (zh) | Cdk8/19抑制劑 | |
| CN109180681A (zh) | 一种dna毒性二聚体化合物 | |
| JP2025516359A (ja) | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 | |
| CN101181647B (zh) | 仿生磷脂聚合物细胞膜及其制备方法和用途 | |
| WO2010148632A1 (zh) | 二氢吡啶类化合物及其制备方法、药物组合物和用途 | |
| CN110734426B (zh) | 乙酰胆碱酯酶降解化合物及其制备方法和应用 |